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Abstract
Cell transplantation for the treatment of joint disease is an important clinical tool. Genetic modification of cells
before transplantation has shown enhanced healing. Ex vivo genetic modification of joint tissue cells with various
adeno-associated virus (AAV) serotypes has not been investigated. The transduction efficiencies of self-
complementary AAV serotypes (1–6 and 8) were determined in joint tissue containing chondrocytes and
synoviocytes isolated from equine models. When comparing scAAV serotypes for efficient transduction ex vivo,
in chondrocytes versus synoviocytes, serotypes 6 and 2, and serotypes 3 and 2, respectively, appeared superior
for gene expression. Unlike adenoviral vectors, no upregulation of inflammatory markers, such as matrix me-
talloproteinases and aggrecanase, was seen on treatment of joint tissue with AAV vectors ex vivo. Our findings
also corroborate that ex vivo transduction of joint tissue can result in high transgene protein levels over time, and
transplantation modalities might be feasible using AAV vectors in the treatment of joint-related diseases.
The field of gene therapy has shown much promise inthe area of musculoskeletal diseases, specifically arthritis
(Evans and Robbins, 1994; Ghivizzani et al., 1998; Goater et al.,
2000; Kafienah et al., 2003; Evans, 2004; Evans et al., 2004;
Goodrich et al., 2006, 2007). There are myriad proteins that
have been identified as decreasing catabolism and increasing
anabolism in joints through targeting the main cell types,
chondrocytes and synoviocytes (Ulrich-Vinther, 2007). Gene
therapy using both in vivo and ex vivo approaches offers the
potential of longer term protein expression than recombinant
proteins and benefits such as steady state protein expression,
delivery of proteins to cells surrounded by matrix such as
chondrocytes in the deep layers of cartilage, and higher
overall levels of therapeutic proteins. In addition, further
development of stem cell therapy strengthens the need to
maximize ex vivo gene delivery.
Various viral and nonviral vectors have been studied in
the field of gene therapy for arthritis (Evans, 2004; Evans
et al., 2004; Gouze et al., 2002, 2003, 2004). Recombinant
adeno-associated viral (AAV) vectors are highly attractive
vectors for the treatment of joint diseases by virtue of their
ability to promote long-term expression and to infect non-
dividing cells, and because of the broad tissue tropism ex-
hibited by AAV serotypes (Ulrich-Vinther, 2007). To date,
most studies of joint tissues have used recombinant AAV
(rAAV) serotype 2 (Madry et al., 2003, 2005; Cucchiarini and
Madry, 2005; Ulrich-Vinther et al., 2005; Dai and Rabie,
2007a). However, the prevalence of antibodies against this
serotype is high in the human population (Grimm and Kay,
2003) and one study by Adriaansen and colleagues reported
a significantly greater immune response to rAAV2 compared
with rAAV5 when injected into the ankle joints of rats
(Adriaansen et al., 2005). At present, at least 12 naturally
occurring serotypes of AAV have been isolated, cloned, and
sequenced (AAV1 to AAV12) (Choi et al., 2005; Gao et al.,
2005; Schmidt et al., 2008). Studies conducted in various
skeletal tissues have revealed a wide array of tissue trans-
duction efficiencies depending on serotype (Riviere et al.,
2006; Dai and Rabie, 2007b). In 2001, McCarty and colleagues
reported increased efficacy of rAAV vectors by synthesizing
a self-complementary recombinant AAV vector (scAAV) that
spontaneously reanneals, alleviating the requirement rAAV
has for host cell DNA synthesis (McCarty et al., 2001). By-
passing rate-limiting second-strand DNA synthesis within
the host cell resulted in 5- to 140-fold more efficient trans-
duction than conventional rAAV (McCarty et al., 2001). This
step becomes more important when considering cell types
that have little to no DNA replication taking place (i.e.,
neurons, cardiomyocytes, and chondrocytes). This has direct
implications for the successful use of scAAV vectors to treat
joint diseases because the cells of joints have a low rate of cell
division.
Previous studies have shown that ex vivo genetic modifi-
cation of cells before implantation can enhance cartilage
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healing (Hidaka et al., 2003; Goodrich et al., 2005, 2007;
Madry et al., 2005). No investigations have been performed
that evaluate the efficacy of various scAAV serotypes ex vivo,
before transplantation. Typically, these cells are implanted
into a cartilage defect 48–72 hr after transduction (Hidaka
et al., 2003; Goodrich et al., 2007). Establishment of the ap-
propriate scAAV serotype to maximize transduction of these
cells would be of great interest to clinicians and researchers
using this important clinical tool.
In an effort to determine the maximal ex vivo transduction
efficiency of scAAV vectors in joint tissues, we tested scAAV
serotypes 1, 2, 3, 4, 5, 6, and 8 (scAAV1–6 and scAAV8) in
chondrocytes and synoviocytes. Initial screening tests were
first performed to evaluate transduction. Further testing was
performed with optimal serotypes to evaluate transduction
efficiency, appropriate viral dose, potential cell toxicity,
length of protein expression, and cytokine response to sero-
types. To the best of our knowledge, this is the first study to
FIG. 1. Initial screening of scAAVGFP1, 2, 3, 4, 5, 6 and 8 in (A) chondrocytes and (B) synoviocytes in monolayer cell culture
on day 7. scAAV2, 3, 5, and 6 had the greatest amount of GFP expression. The viral dose of 10,000 viral particles per cell
(VPC) had the highest percentage transduction. Bottom labels indicate serotypes and right column labels indicate the VPC.
Original magnification,40.
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evaluate scAAV serotypes in chondrocytes and synoviocytes.
The data described herein will be relevant for the design of
future ex vivo transduction studies involving scAAV vectors
in therapeutic gene transfer to joint tissue.
All scAAV vectors used in this study were provided by
the Gene Therapy Center Vector Core Facility (Chapel Hill,
CA). The scAAVGFP construct (pHpa-trs-SK) used in this
study has been described previously (McCarty et al., 2001)
and cross-packaging in various serotype capsids was per-
formed as described (Rabinowitz et al., 2002). Statistical
analysis involved one-way analysis of variance (ANOVA) of
all continuous data with Tukey post-hoc comparison when
statistical significance was detected. Ordinal data (viability
and cells scores) were analyzed by Kruskal–Wallis test. Sta-
tistical significance was determined when p 0.05 and a
trend was noted when 0.05< p< 0.1.
For preliminary screening of AAV serotypes, chon-
drocytes and synoviocytes were harvested from femor-
opatellar joints of neonatal foals (1 to 2 days old) at
postmortem, and stored in liquid nitrogen until ready for use
(Nixon et al., 1992). Cells were thawed for plating as previ-
ously described (Brower-Toland et al., 2001; Saxer et al., 2001)
and monolayer cultures in HEPES-buffered F-12 medium
with 10% fetal bovine serum (FBS) (GIBCO, Grand Island,
NY) at 50% confluence were established in 24-well plates.
One day after seeding, cells were transduced with scAAV1–6
and scAAV8 packaging the green fluorescent protein (GFP)-
encoding transgene driven by the cytomegalovirus (CMV)
promoter at various levels of viral particles per cell (VPC).
Fluorescence micrographs were obtained every 3 days for the
first 30 days and then weekly for up to 90 days to monitor
GFP expression. As shown in Fig. 1, preliminary screening of
scAAVGFP serotypes revealed that scAAV2, 3, 5, and 6
transduced chondrocyte=synoviocyte cultures at high effi-
ciency by day 7. scAAV1, 4, and 8 had minimal GFP ex-
pression at all of the viral doses tested in both chondrocytes
and synoviocytes. Transduction efficiencies of serotypes at
10,000 VPC followed the order scAAV2> scAAV6> scAAV3
in chondrocytes (Fig. 1A) and scAAV2> scAAV3> scAAV6
in synoviocytes (Fig. 1B). Although scAAV5GFP was not
tested at this VPC dose (due to low titer), these vectors ap-
peared to transduce joint tissue with efficiency similar to
scAAV3 and scAAV6 vectors at 1000 VPC.
This observed trend is in general agreement with other
studies that demonstrate serotype selectivity in skeletal
muscle (Riviere et al., 2006) or chondrocytes and bone
marrow-derived mesenchymal stem cells (Dai and Rabie,
2007a). In a later study by Dai and colleagues, however,
rAAV serotype 1 appeared to transduce rat chondrocytes
efficiently (Dai and Rabie, 2007b), which is in contrast to our
findings in the equine model. This can likely be attributed to
species-specific differences in tissue tropism of AAV sero-
types (Duan et al., 2000; Sanlioglu et al., 2001), and stresses
the need to test various AAV serotypes in the species of
interest before testing therapeutic transgenes.
On the basis of this preliminary screening, we quantitated
the transduction efficiency of scAAV2, 3, 5, and 6 in chon-
drocytes and synoviocytes by flow cytometry-assisted cell
sorting on days 7 and 14 posttransduction. Briefly, sorting
was conducted with a MoFlo cell sorter=analyzer (Beckman
Coulter, Fullerton, CA) with a 100-mm flow cell tip used at a
sheath pressure of 30 psi and a flow rate of 12,000 events per
second, with a laser line of 488 nm and a laser power of 110.
Cells were sorted on the basis of GFP fluorescence with a
530=540 bandpass filter, preceded by a neutral-density 2.0
filter and high voltage of 400–450 with a log signal. Summit
software (version 4.0; Beckman Coulter) was used to collect
histograms and set sort parameters. As shown in Fig. 2A, on
day 7, 95–99% GFP-positive cells were detected for scAAV2,
3, 5, and 6 at 4000 VPC in chondrocytes. No significant dif-
ferences were seen in transduction efficiencies between the
serotypes (~85–90% GFP-positive cells) for scAAV2, 3, 5, and
6 at a dose of 4000 VPC. Of the dosing groups, AAV3 and
AAV5 had significantly better transduction efficiencies at
4000 VPC than at 1000 VPC and within the dosing groups,
AAV2 at 2000 VPC had significantly greater transducing ef-
ficiency than AAV3. However, as seen in Fig. 2B, analysis of
samples on day 14 revealed a statistically significant lower
transduction efficiency for scAAV5 (~36% GFP-positive cells)
in comparison with scAAV2 at 2000 VPC. Dose did not affect
serotype transduction efficiency on day 14 except for AAV3,
for which 4000 VPC was better than 1000 VPC. In synovio-
cytes, a transduction efficiency of 85–100% (GFP-positive cells)
was seen for each serotype tested on day 7 posttransduction
(Fig. 3A). AAV3 had a higher transduction efficiency at 4000
and 2000 VPC than at 1000 VPC. At 14 days there were no
significant differences between AAV serotypes 2, 3, 5, and 6 at
any dose. Further, there were no significant differences within
any serotype at doses of 4000, 2000, and 1000 VPC (Fig. 3B).






























































Transduction efficiency in chondrocytes day 14
Transduction efficiency in chondrocytes day 7
FIG. 2. Quantitative analysis (flow cytometry-assisted cell
sorting) of the transduction efficiency of scAAVGFP2, 3, 5,
and 6. Transduction was performed on chondrocytes in
monolayer at (A) 7 days and (B) 14 days. Flow cytometry
was performed on days 7 and 14 after transduction with
4000, 2000, and 1000 VPC. Capital letters denote significant
differences in titer within serotypes, and uncapitalized letters
denote significant differences between serotypes within each
titer tested.
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approximately 2 days after transduction and reached maximal
fluorescence at approximately 5 days after transduction.
At 14 days both chondrocytes and synoviocytes were
approximately doubled in number from day 7, which ac-
counts for the 50% decrease in the number of cells emitting
GFP. This decrease in GFP-positive cell number over time
can be attributed to dilution of AAV vector genomes and is
expected because of the persistence of AAV vector genomes
in episomal rather than integrated form (Bartlett et al., 2000).
At 51 days, both chondrocytes and synoviocytes had at least
30% GFP-positive cells when transduced with AAV2 or
AAV6 (data not shown). This long-term expression is en-
couraging for therapeutic gene transfer applications in car-
tilage healing, osteoarthritis, and rheumatoid arthritis, for
which the healing time required is prolonged compared with
soft tissue (months vs. days) (Sams and Nixon, 1993; Hen-
drickson et al., 1994).
For cell viability studies, trypan blue staining and mor-
phological studies were carried out on days 0, 3, 7, 10, and 14
posttransduction. Cells were given a score of 0 through 5 on
the basis of morphological characteristics. Abnormal mor-
phological characteristics were considered to be rounding,
crenation, or lifting off the plate. A score of 1¼ 1–20% of the
cells had abnormal cell morphology, 2¼ 21–40, 3¼ 41–60,
4¼ 61–80, and 5¼ 81–100%. Five views at 200 magnifica-
tion were assessed and an average score was determined. As
outlined in Table 1, scAAV2 vectors appear to have some
negative impact on both chondrocytes and synoviocytes,
based on the observation that several cells became rounded,
crenated, or detached from the plate. A trend (0.05< p< 0.1)
was detected on days 7, 10, and 14, wherein scAAV2GFP
had the highest score (greatest morbidity) at each time point.
The reason behind this effect is not clear. No significant differ-
ences were detected for viability between any serotype or titer.






















3 0 (0) 1.7 (2.1) 0.7 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.7 (1.2) 0 (0) 0 (0)
7 0 (0) 2.7 (1.2)b 2.3 (0.6)b 2.0 (1) 0 (0) 0.3 (0.6) 0.3 (0.6) 0.7 (0.6) 0 (0) 0.3 (0.6) 0 (0) 0.3 (0.6)
10 0 (0) 3 (1)b 2.7 (1.2)b 2.3 (1.5) 0 (0) 1.3 (0.6) 1.0 (0) 1.0 (0) 0 (0) 1.3 (1.2) 1 (1.0) 1 (1.0)
14 0 (0) 3 (1)b 2.7 (1.2)b 2.3 (1.5) 0 (0) 1.3 (0.6) 0.7 (0.6) 0.7 (0.6) 0 (0) 1.0 (1.0) 0.7 (0.6) 0.7 (0.6)
Chondrocyte Viability
7 94 (2) 81 (21) 87 (5) 94 (2) 90 (7) 94 (3) 94 (4) 91 (5) 96 (4) 85 (9) 86 (14) 73 (17)
14 91 (9) 79 (20) 85 (5) 94 (5) 86 (10) 91 (5) 83 (14) 88 (3) 85 (8) 93 (6) 92 (7) 79 (16)
Synoviocyte Morphology Scores
3 0 (0) 2.7 (0.6)c 1.7 (0.6)b 1.0 (1.0) 0 (0) 1.0 (1.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
7 0 (0) 2.7 (0.6)c 2.0 (0)b 1.3 (0.6) 0 (0) 0.3 (0.6) 0 (0) 0.3 (0.6) 0 (0) 0 (0) 0 (0) 0 (0)
10 0 (0) 2.3 (1.2)c 1.7 (0.6)b 1.3 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.3 (0.6) 0.3 (0.6) 0 (0)
14 0 (0) 2.0 (1.0)c 1.7 (0.6)b 1.3 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.3 (0.6) 0.3 (0.6) 0 (0)
Synoviocyte Viability
7 92 (2) 66 (18) 81 (9) 80 (22) 94 (2) 83 (12) 87 (6) 85 (3) 90 (6) 81 (13) 87 (5) 95 (4)
14 85 (4) 63 (28) 83 (14) 75 (17) 85 (11) 83 (15) 79 (11) 73 (18) 77 (10) 67 (14) 68 (30) 36 (12)
Abbreviations: scAAV2, 3, and 5; self-complementary AAV serotypes 2, 3, and 5; VPC¼viral particles per cell.
aResults are given with standard deviation in parentheses.
bA trend (0.05< p< 0.1) toward significant morphological changes compared with control cells.




















































Transduction efficiency in synoviocytes day 14
A B
A A B
FIG. 3. Quantitative analysis (flow cytometry-assisted cell sorting) of the transduction efficiency of scAAVGFP2, 3, 5, and 6.
Transduction was performed on synoviocytes in monolayer at (A) 7 days and (B) 14 days. Flow cytometry was performed on
days 7 and 14 after transduction with 4000, 2000, and 1000 VPC. Capital letters denote significant differences in titers within
serotypes.
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Last, matrix metalloproteinases (MMPs) and aggrecanase
levels are considered a good representation of inflammatory
changes in joint tissues (Ishiguro and Kojima, 2004). An in-
crease in these molecules has been noted with adenoviral
vectors (Goodrich et al., 2007). Therefore, in an effort to detect
any inflammatory response to AAV serotypes, we carried
out quantitative RT-PCR assays to monitor the impact of
AAV vectors on expression levels of equine MMP-1, MMP-3,
MMP-13, and aggrecanase-1, markers of the inflammatory
response in joint tissue. Briefly, RNA was extracted from
cells on day 7, using a QIAshredder and RNeasy mini kit
(Qiagen, Valencia, CA), and complementary DNA was
generated using 50 ng of total RNA and oligo(dT) primers
with a SuperScript III first-strand synthesis kit (Invitrogen,
Carlsbad, CA). mRNA expression of target genes was com-
pared with the expression levels of equine glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as control. Equine
MMP-1, MMP-3, MMP-13, and GAPDH primer=probes were
obtained from the Lucy Whittier Molecular & Diagnostic
Core Facility (University of California Davis, Davis, CA).
Primer sequences were as follows: MMP-1 forward, 50-AAG
CTGCTTATGAGGTTTCCCA; reverse, 50-GGGTATCCGTA
GAGCACATCCT; probe, 50-FAM-AGCCCAGTACTTATTA




were as follows: forward, 50-GCCTTCACTGCTGCTCATGA;
reverse, 50-CCAACACATGGCTTTGAATTGT; and probe,
50-FAM-CTGGGCCATGTCTTCAACATGCTCC-TAMRA-30.
Quantitative RT-PCR was performed, with 2.5 ng of RNA
per sample (in duplicate) and a 384-well LightCycler 480
(Roche, Indianapolis, IN). Sample cycle threshold data were
normalized to standards for each gene and compared with
each other by determining the ratio of the gene of interest to
GAPDH. No significant trends were noted in the inflam-
matory response to AAV vectors, with the overall effects
being negligible. Although not statistically significant, a
slight increase in aggrecanase RNA expression was noted in
both chondrocytes and synoviocytes for scAAV3 vectors.
These results seem to be consistent with published obser-
vations that AAV, when compared with other DNA viruses
(e.g., adenovirus), is dramatically different with respect to
the acute immune response (Wu et al., 2006).
In conclusion, this study identified four serotypes of
scAAV that are effective in transducing primary chon-
drocytes and synoviocytes ex vivo. This is of significant
importance because implantation of primary cells (chon-
drocytes and synoviocytes) for joint therapy in both human
and equine patients is routine for osteochondritis dissecans
(OCD) and acute cartilage traumatic lesions and would
dramatically benefit from therapeutic gene transfer aug-
mentation (IGF-I, IRAP, and BMP-7) (Marlovits et al., 2004;
Fortier and Nixon, 2005). In chondrocytes, scAAV6 and
scAAV2 appear to be the most efficient whereas in syno-
viocytes, scAAV3 and scAAV2 were more robust. With the
identification of surface receptors for AAV1, 2, 4, 5, and 6
(Wu et al., 2006), and the high degree of sequence homology
between AAV2 and AAV3 (88%), the potential for this in-
formation to facilitate the generation and testing of chimeric
AAV particles with improved chondrocyte and synovial cell
transduction is imminent (Wu et al., 2006). We have suc-
cessfully transplanted chondrocytes in a lesion in equine
joints and tracked cell viability out to 9 weeks (Goodrich
et al., 2005). These observations and our findings that self-
complementary AAV can efficiently transduce joint tissue ex
vivo, resulting in high transgene protein levels over time,
have set the stage for evaluating genetically modified ther-
apeutic cells for transplantation in diseased joints.
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